Physician profile

Michael D Rigby

Sports Medicine (Family Medicine) · Greensboro, NC

NPI 1649532110

$698.32

in general payments reported to CMS, 2019-2025

9 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$71.51

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Amgen INC. $277.85 2021-2023 Evenity, Prolia
Radius Health, INC. $160.98 2021-2022
Spr Therapeutics, INC $74.14 2022-2023 Sprint Pns System
Pacira Therapeutics, INC. $66.73 2019-2021
Depuy Synthes Sales INC. $60.22 2019
Glaxosmithkline, LLC. $17.43 2020
Boehringer Ingelheim Pharmaceuticals, INC. $16.78 2019
Novo Nordisk INC $12.66 2020
Lilly USA, LLC $11.53 2019

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Michael D Rigby

$698.32

in general payments reported 2019-2025

Years
2019-2023
Top company
Amgen INC.

https://glasscript.com/doctor/723916/michael-d-rigby

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.